MAA
LLY icon

Mraz Amerine & Associates’s Eli Lilly LLY Stock Holding History

Mraz Amerine & Associates’s Portfolio LLY Stock Details LLY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-225
Closed -$242K – 197
2025
Q4 		$242K Sell
225
-90
-29% -$86.1K 0.04% 156
2025
Q3 		$240K Buy
315
+3
+1% +$2.23K 0.04% 157
2025
Q2 		$243K Buy
312
+50
+19% +$38.9K 0.04% 164
2025
Q1 		$215K Hold
262
– – 0.04% 151
2024
Q4 		$202K Hold
262
– – 0.04% 151
2024
Q3 		$232K Buy
+262
New +$236K 0.04% 147

Other funds holding LLY

Lilly Endowment
Lilly Endowment Indiananapolis, Indiana $108B AUM 53.87% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PNC Financial Services Group
PNC Financial Services Group Pittsburgh, Pennsylvania $202B AUM 37.79% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Mraz Amerine & Associates's LLY Position: Q1 2026 in Review

Mraz Amerine & Associates sold out of Eli Lilly (LLY) in Q1 2026, closing a stake of 225 shares — an estimated $242K sold.

Mraz Amerine & Associates first reported a position in LLY in Q3 2024 and held it in 6 quarters. The position peaked at $243K in Q2 2025. 4,389 funds tracked by Wall St. Rank hold LLY as of Q1 2026.

  • Mraz Amerine & Associates reported no remaining Eli Lilly position as of Q1 2026 after selling out during the quarter.
  • Mraz Amerine & Associates sold 225 Eli Lilly shares in Q1 2026, an estimated $242K.
  • Mraz Amerine & Associates first reported a position in Eli Lilly in Q3 2024 and held it in 6 quarters.
  • Mraz Amerine & Associates's Eli Lilly position peaked at $243K in Q2 2025.
  • 4,389 funds tracked by Wall St. Rank held Eli Lilly as of Q1 2026.

Based on Mraz Amerine & Associates's 13F filing for Q1 2026, filed 5 May 2026.